UK Court Favors Novartis In Lucentis Patent Suit
A U.K. judge ruled Tuesday that Novartis Pharmaceuticals U.K. Ltd.'s vision-loss drug Lucentis does not infringe two patents held by AstraZeneca PLC unit MedImmune Ltd....To view the full article, register now.
Already a subscriber? Click here to view full article